Clearmind Medicine Announces 1-for-10 Reverse Share Split to Regain Nasdaq Compliance

On May 19, 2026, Clearmind Medicine Inc. (Nasdaq: CMND) announced that it will implement a 1-for-10 reverse share split of its common shares. The reverse split is scheduled to take effect for trading purposes on the Nasdaq Capital Market on Thursday, May 21, 2026. This corporate action is intended to help the company regain compliance with the Nasdaq Minimum Bid Price Rule. The reverse split will reduce the number of issued and outstanding common shares from approximately 10,190,337 to approximately 1,019,033 shares. No fractional shares will be issued; instead, all fractional shares will be rounded up to the nearest whole share. Additionally, proportionate adjustments will be made to the exercise prices and the number of shares issuable under the company's outstanding warrants and options. Clearmind Medicine is a clinical-stage biotech firm focusing on non-hallucinogenic, neuroplastogen-derived therapeutics for health issues such as alcohol use disorder. The company's authorized share capital remains unchanged following this split.